Delta Asset Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Hold |
0
| – | -$4 | – | 696 |
|
|
2023
Q4 | – | Hold |
0
| – | – | – | 680 |
|
|
2023
Q3 | – | Hold |
0
| – | – | – | 649 |
|
|
2023
Q2 | – | Hold |
0
| – | – | – | 654 |
|
|
2023
Q1 | – | Hold |
0
| – | – | – | 634 |
|
|
2022
Q4 | – | Hold |
0
| – | – | – | 667 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 620 |
|
|
2021
Q4 | – | Hold |
0
| – | – | – | 651 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 652 |
|
|
2021
Q2 | – | Hold |
0
| – | – | – | 624 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 620 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 607 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 620 |
|
|
2020
Q2 | – | Hold |
0
| – | – | – | 639 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 653 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 628 |
|
|
2019
Q3 | – | Sell |
-9
| Closed | -$921 | – | 622 |
|
|
2019
Q2 | $1K | Hold |
9
| – | – | ﹤0.01% | 543 |
|
|
2019
Q1 | $1K | Hold |
9
| – | – | ﹤0.01% | 544 |
|
|
2018
Q4 | $1K | Sell |
9
-7
| -44% | -$1.4K | ﹤0.01% | 643 |
|
|
2018
Q3 | $4K | Hold |
16
| – | – | ﹤0.01% | 566 |
|
|
2018
Q2 | $34K | Hold |
16
| – | – | 0.01% | 289 |
|
|
2018
Q1 | $40K | Hold |
16
| – | – | 0.01% | 261 |
|
|
2017
Q4 | $29K | Hold |
16
| – | – | ﹤0.01% | 305 |
|
|
2017
Q3 | $18K | Hold |
16
| – | – | ﹤0.01% | 349 |
|
|
2017
Q2 | $12K | Hold |
16
| – | – | ﹤0.01% | 393 |
|
|
2017
Q1 | $11K | Hold |
16
| – | – | ﹤0.01% | 408 |
|
|
2016
Q4 | $11K | Hold |
16
| – | – | ﹤0.01% | 404 |
|
|
2016
Q3 | $18K | Sell |
16
-5
| -24% | -$4.36K | ﹤0.01% | 337 |
|
|
2016
Q2 | $16K | Buy |
21
+8
| +62% | +$7.48K | ﹤0.01% | 361 |
|
|
2016
Q1 | $9K | Hold |
13
| – | – | ﹤0.01% | 423 |
|
|
2015
Q4 | $14K | Hold |
13
| – | – | ﹤0.01% | 375 |
|
|
2015
Q3 | $14K | Hold |
13
| – | – | ﹤0.01% | 371 |
|
|
2015
Q2 | $28K | Hold |
13
| – | – | 0.01% | 291 |
|
|
2015
Q1 | $12K | Hold |
13
| – | – | ﹤0.01% | 404 |
|
|
2014
Q4 | $14K | Buy |
13
+8
| +160% | +$7.14K | ﹤0.01% | 391 |
|
|
2014
Q3 | $5K | Hold |
5
| – | – | ﹤0.01% | 494 |
|
|
2014
Q2 | $10K | Hold |
5
| – | – | ﹤0.01% | 420 |
|
|
2014
Q1 | $11K | Hold |
5
| – | – | ﹤0.01% | 405 |
|
|
2013
Q4 | $12K | Sell |
5
-5
| -50% | -$11.4K | ﹤0.01% | 391 |
|
|
2013
Q3 | $27K | Buy |
10
+5
| +100% | +$24.9K | 0.01% | 290 |
|
|
2013
Q2 | $46K | Buy |
+5
| New | +$38.5K | 0.01% | 223 |
|
Other funds holding ONCT
QPW
RB
BJL
Delta Asset Management's ONCT Position: Q1 2024 in Review
Delta Asset Management held its Oncternal Therapeutics, Inc. Common Stock (ONCT) position steady in Q1 2024 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #696.
Delta Asset Management first reported a position in ONCT in Q2 2013 and has held it in 25 quarters since. The position peaked at $46K in Q2 2013. 24 funds tracked by Wall St. Rank hold ONCT as of Q1 2024.
- Delta Asset Management held 0 shares of Oncternal Therapeutics, Inc. Common Stock worth $0 as of Q1 2024.
- Delta Asset Management left its Oncternal Therapeutics, Inc. Common Stock share count unchanged in Q1 2024.
- Oncternal Therapeutics, Inc. Common Stock made up ﹤0.01% of Delta Asset Management's portfolio in Q1 2024, its #696 holding.
- Delta Asset Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and has held it in 25 quarters since.
- Delta Asset Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $46K in Q2 2013.
- 24 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Delta Asset Management's 13F filing for Q1 2024, filed 13 May 2024.